Bacterial Vaginosis Treatment
For non-pregnant women with symptomatic bacterial vaginosis, treat with metronidazole 500 mg orally twice daily for 7 days or metronidazole gel 0.75% intravaginally once daily for 5 days, as these regimens are equally efficacious and represent first-line therapy. 1
Non-Pregnant Women
First-Line Treatment Options (Equally Effective)
- Metronidazole 500 mg orally twice daily for 7 days
- Metronidazole gel 0.75% intravaginally once daily for 5 days
- Clindamycin cream 2% intravaginally at bedtime for 7 days (less efficacious than metronidazole regimens) 1
Important counseling point: Patients must avoid alcohol during metronidazole treatment and for 24 hours after completion. Clindamycin cream is oil-based and weakens latex condoms and diaphragms. 1
Alternative Regimens (Lower Efficacy)
- Metronidazole 2 g orally single dose (lower efficacy, use only when adherence is a concern)
- Clindamycin 300 mg orally twice daily for 7 days
- Clindamycin ovules 100 g intravaginally at bedtime for 3 days 1
Recurrent Bacterial Vaginosis
For recurrent disease (defined as recurrence after initial treatment), use metronidazole 500 mg twice daily for 10-14 days; if this fails, switch to metronidazole gel 0.75% for 10 days followed by twice weekly maintenance for 3-6 months. 2 Recurrence occurs in 50-80% of women within one year, likely due to biofilm formation and failure of beneficial Lactobacillus species to recolonize 3, 2.
Pregnant Women
Symptomatic Pregnant Women
All symptomatic pregnant women must be tested and treated with systemic therapy to reduce adverse pregnancy outcomes including preterm birth, premature rupture of membranes, chorioamnionitis, and postpartum endometritis. 1
Recommended regimens for pregnancy:
- Metronidazole 250 mg orally three times daily for 7 days (note the lower dose than non-pregnant regimen)
- Clindamycin 300 mg orally twice daily for 7 days 1
Critical caveat: Do NOT use topical agents (clindamycin cream or metronidazole gel) during pregnancy. Three trials demonstrated increased adverse events including prematurity and neonatal infections with clindamycin cream use in pregnancy. 1 Multiple meta-analyses confirm metronidazole has no teratogenic or mutagenic effects in pregnancy. 1
Asymptomatic Pregnant Women at High Risk
For asymptomatic pregnant women with a history of prior preterm delivery, screening and treatment at the first prenatal visit may reduce preterm birth risk (reduced preterm delivery in 3 of 4 randomized trials). Use the same oral regimens as for symptomatic pregnant women. 1
Follow-up evaluation at 1 month after treatment completion should be considered in high-risk pregnant women to confirm cure. 1
For asymptomatic low-risk pregnant women (no history of preterm birth), current evidence does not support universal screening or treatment. 4, 1
Special Considerations
Metronidazole Allergy or Intolerance
Use clindamycin cream or oral clindamycin. Patients with true metronidazole allergy should NOT receive metronidazole gel vaginally. 1
Partner Treatment
Do NOT treat male partners routinely. Clinical trials demonstrate that partner treatment does not affect cure rates or recurrence risk. 1
Follow-Up
Follow-up visits are unnecessary if symptoms resolve. No long-term maintenance regimen is recommended for non-pregnant women (except in recurrent cases as noted above). 1
HIV-Infected Patients
Use the same treatment regimens as HIV-negative patients. 1
Key Clinical Pitfalls to Avoid
- Do not use topical agents in pregnancy - associated with worse neonatal outcomes
- Do not use the 500 mg twice daily metronidazole dose in pregnancy - use the 250 mg three times daily regimen instead
- Do not treat asymptomatic low-risk pregnant women - no proven benefit
- Do not treat partners - wastes resources without improving outcomes
- Do not use single-dose metronidazole 2g as first-line - inferior efficacy compared to 7-day regimens